Tumor neoantigens: building a framework for personalized cancer immunotherapy

Articles citing Tumor neoantigens: building a framework for personalized cancer immunotherapy

Title / Author	Year
Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers AM Goodman, S Kato, L Bazhenova, SP Patel, GM Frampton, V Miller, ... Molecular cancer therapeutics 16 (11), 2598-2608	2017
Targeting neoantigens to augment antitumour immunity M Yarchoan, BA Johnson III, ER Lutz, DA Laheru, EM Jaffee Nature Reviews Cancer 17 (4), 209	2017
NetMHCpan-4.0: improved peptide–MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data V Jurtz, S Paul, M Andreatta, P Marcatili, B Peters, M Nielsen The Journal of Immunology 199 (9), 3360-3368	2017
Cancer immunotherapy: harnessing the immune system to battle cancer Y Yang The Journal of clinical investigation 125 (9), 3335-3337	2015
Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis S Turajlic, K Litchfield, H Xu, R Rosenthal, N McGranahan, JL Reading, ... The lancet oncology 18 (8), 1009-1021	2017
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy W Ma, BM Gilligan, J Yuan, T Li Journal of hematology & oncology 9 (1), 47	2016
A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy M Łuksza, N Riaz, V Makarov, VP Balachandran, MD Hellmann, ... Nature 551 (7681), 517-520	2017
Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy Y Min, KC Roche, S Tian, MJ Eblan, KP McKinnon, JM Caster, S Chai, ... Nature nanotechnology 12 (9), 877	2017
Molecular and translational classifications of DAMPs in immunogenic cell death AD Garg, L Galluzzi, L Apetoh, T Baert, RB Birge, BS Pedro, J Manuel, ... Frontiers in immunology 6, 588	2015
Tailoring biomaterials for cancer immunotherapy: Emerging trends and future outlook C Wang, Y Ye, Q Hu, A Bellotti, Z Gu Advanced materials 29 (29), 1606036	2017
Cancer immunoediting and resistance to T cell-based immunotherapy JS O’Donnell, MWL Teng, MJ Smyth Nature reviews Clinical oncology 16 (3), 151-167	2019
Cell death and immunity in cancer: from danger signals to mimicry of pathogen defense responses AD Garg, P Agostinis Immunological reviews 280 (1), 126-148	2017
Applications of immunogenomics to cancer XS Liu, ER Mardis Cell 168 (4), 600-612	2017
The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine A Garofalo, L Sholl, B Reardon, A Taylor-Weiner, A Amin-Mansour, ... Genome medicine 8 (1), 1-10	2016
MHCflurry: open-source class I MHC binding affinity prediction TJ O'Donnell, A Rubinsteyn, M Bonsack, AB Riemer, U Laserson, ... Cell systems 7 (1), 129-132. e4	2018
Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy A Rotte, JY Jin, V Lemaire Annals of Oncology 29 (1), 71-83	2018
The role of neoantigens in naturally occurring and therapeutically induced immune responses to cancer JP Ward, MM Gubin, RD Schreiber Advances in immunology 130, 25-74	2016
Trial watch: immunogenic cell death induction by anticancer chemotherapeutics AD Garg, S More, N Rufo, O Mece, ML Sassano, P Agostinis, L Zitvogel, ... Oncoimmunology 6 (12), e1386829	2017
A facile approach to enhance antigen response for personalized cancer vaccination AW Li, MC Sobral, S Badrinath, Y Choi, A Graveline, AG Stafford, ... Nature materials 17 (6), 528-534	2018
Targeting the heterogeneity of cancer with individualized neoepitope vaccines Ö Türeci, M Vormehr, M Diken, S Kreiter, C Huber, U Sahin Clinical Cancer Research 22 (8), 1885-1896	2016

1 - 20

Dates and citation counts are estimated and are determined automatically by a computer program.